SUBSCRIBE: Print / eNewsletter
Check out our resource centers on specific hematologic malignancies for the latest news and information on the treatment of these diseases.
Ponatinib Extends Survival Over Transplant in Chronic Phase CML
Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.
RVD Plus Transplantation Delayed Progression in Myeloma
Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.
Pacritinib Induced Reduction in Splenomegaly, Myelofibrosis Symptoms
The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.
Relapsed, Refractory Myeloma Has Indirect Societal Costs
Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.
TKIs Associated With Subclinical Pulmonary Hypertension in CML Patients
Treatment of CML with tyrosine kinase inhibitors including imatinib, nilotinib, and dasatinib can be associated with subclinical pulmonary hypertension.
‘VCD-Lite’ Viable Option for Older, Toxicity-Vulnerable Myeloma Patients
Dose-attenuated bortezomib, cyclophosphamide, and dexamethasone (VCD-lite) is a viable treatment option for vulnerable or frail adults with newly diagnosed multiple myeloma.
Hodgkin Lymphoma Survivors at High Risk for Second Cancers
Patients who have survived Hodgkin lymphoma were at more than double the risk for diagnosis with a second cancer, according to the results of a recent study.
Leucocyte Marker in Pediatric ALL Linked With Relapse-Free Survival
During maintenance therapy for childhood ALL, there was a general increase in DNA-incorporated thioguanine nucleotides (DNA-TGN), and this increase was associated with a lower frequency of disease relapse.
Escalated BEACOPP Plus Rituximab in Advanced Hodgkin Lymphoma Fails to Improve Outcomes
Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma.